GeneDx (WGS) Competitors $77.40 +2.10 (+2.79%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends WGS vs. HIMS, GH, OPCH, SHC, VCYT, BTSG, LFST, SGRY, CON, and PRVAShould you be buying GeneDx stock or one of its competitors? The main competitors of GeneDx include Hims & Hers Health (HIMS), Guardant Health (GH), Option Care Health (OPCH), Sotera Health (SHC), Veracyte (VCYT), BrightSpring Health Services (BTSG), LifeStance Health Group (LFST), Surgery Partners (SGRY), Concentra Group Holdings Parent (CON), and Privia Health Group (PRVA). These companies are all part of the "healthcare" industry. GeneDx vs. Hims & Hers Health Guardant Health Option Care Health Sotera Health Veracyte BrightSpring Health Services LifeStance Health Group Surgery Partners Concentra Group Holdings Parent Privia Health Group Hims & Hers Health (NYSE:HIMS) and GeneDx (NASDAQ:WGS) are both mid-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, community ranking, dividends, media sentiment, risk, valuation and institutional ownership. Does the MarketBeat Community believe in HIMS or WGS? Hims & Hers Health received 29 more outperform votes than GeneDx when rated by MarketBeat users. However, 47.62% of users gave GeneDx an outperform vote while only 38.61% of users gave Hims & Hers Health an outperform vote. CompanyUnderperformOutperformHims & Hers HealthOutperform Votes3938.61% Underperform Votes6261.39% GeneDxOutperform Votes1047.62% Underperform Votes1152.38% Which has higher valuation and earnings, HIMS or WGS? Hims & Hers Health has higher revenue and earnings than GeneDx. GeneDx is trading at a lower price-to-earnings ratio than Hims & Hers Health, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHims & Hers Health$1.24B4.61-$23.55M$0.4459.55GeneDx$267.23M7.96-$175.77M-$3.11-24.89 Which has more risk and volatility, HIMS or WGS? Hims & Hers Health has a beta of 1.25, suggesting that its share price is 25% more volatile than the S&P 500. Comparatively, GeneDx has a beta of 2.03, suggesting that its share price is 103% more volatile than the S&P 500. Do analysts recommend HIMS or WGS? Hims & Hers Health presently has a consensus price target of $22.80, suggesting a potential downside of 12.98%. GeneDx has a consensus price target of $59.33, suggesting a potential downside of 23.34%. Given Hims & Hers Health's higher possible upside, equities analysts clearly believe Hims & Hers Health is more favorable than GeneDx.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Hims & Hers Health 1 Sell rating(s) 8 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.41GeneDx 0 Sell rating(s) 3 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 Is HIMS or WGS more profitable? Hims & Hers Health has a net margin of 8.19% compared to GeneDx's net margin of -31.25%. Hims & Hers Health's return on equity of 10.97% beat GeneDx's return on equity.Company Net Margins Return on Equity Return on Assets Hims & Hers Health8.19% 10.97% 8.29% GeneDx -31.25%-13.35%-6.91% Does the media favor HIMS or WGS? In the previous week, Hims & Hers Health had 19 more articles in the media than GeneDx. MarketBeat recorded 29 mentions for Hims & Hers Health and 10 mentions for GeneDx. GeneDx's average media sentiment score of 0.51 beat Hims & Hers Health's score of 0.48 indicating that GeneDx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Hims & Hers Health 11 Very Positive mention(s) 5 Positive mention(s) 8 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral GeneDx 5 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals & insiders believe in HIMS or WGS? 63.5% of Hims & Hers Health shares are held by institutional investors. Comparatively, 61.7% of GeneDx shares are held by institutional investors. 17.7% of Hims & Hers Health shares are held by company insiders. Comparatively, 27.3% of GeneDx shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. SummaryHims & Hers Health beats GeneDx on 12 of the 18 factors compared between the two stocks. Ad Behind the MarketsWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Click to get the name and ticker symbol Get GeneDx News Delivered to You Automatically Sign up to receive the latest news and ratings for WGS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart WGS vs. The Competition Export to ExcelMetricGeneDxHealth services IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.13B$867.07M$5.12B$9.07BDividend YieldN/A1.90%4.91%4.22%P/E Ratio-24.8932.2091.3417.19Price / Sales7.963.751,117.70116.80Price / CashN/A25.1442.6437.86Price / Book8.822.924.794.78Net Income-$175.77M-$5.79M$120.07M$225.60M7 Day Performance2.61%-4.93%-1.90%-1.23%1 Month Performance7.40%-4.89%11.45%3.37%1 Year Performance2,664.29%226.77%30.63%16.58% GeneDx Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)WGSGeneDx1.2575 of 5 stars$77.40+2.8%$59.33-23.3%+2,935.3%$2.13B$267.23M-24.891,200Insider TradeGap DownHIMSHims & Hers Health3.3847 of 5 stars$30.93+3.0%$21.43-30.7%+214.3%$6.76B$872M70.251,046Analyst ForecastInsider TradeNews CoverageGHGuardant Health4.1067 of 5 stars$35.13+1.1%$40.60+15.6%+25.6%$4.34B$692.26M-8.201,779OPCHOption Care Health4.8665 of 5 stars$23.40-0.4%$30.14+28.8%-29.9%$3.98B$4.78B19.747,802Positive NewsSHCSotera Health3.5846 of 5 stars$13.01-1.1%$16.08+23.6%-20.0%$3.68B$1.05B52.603,000Positive NewsVCYTVeracyte4.0276 of 5 stars$43.35+0.3%$41.13-5.1%+49.0%$3.36B$361.05M-288.13790Positive NewsBTSGBrightSpring Health Services2.3113 of 5 stars$18.95+2.1%$18.50-2.4%N/A$3.30B$10.59B-71.3835,000Analyst ForecastPositive NewsLFSTLifeStance Health Group1.7047 of 5 stars$7.79+8.6%$8.70+11.7%-0.3%$2.98B$1.21B-29.509,325Positive NewsGap UpSGRYSurgery Partners3.2475 of 5 stars$22.22+9.1%$36.56+64.5%-33.8%$2.82B$2.74B-42.4213,500CONConcentra Group Holdings ParentN/A$21.44+4.6%$28.50+32.9%N/A$2.73B$1.88B0.0011,000PRVAPrivia Health Group2.8954 of 5 stars$21.55+2.8%$24.80+15.1%-12.6%$2.59B$1.66B209.621,102 Related Companies and Tools Related Companies HIMS Competitors GH Competitors OPCH Competitors SHC Competitors VCYT Competitors BTSG Competitors LFST Competitors SGRY Competitors CON Competitors PRVA Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:WGS) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GeneDx Holdings Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share GeneDx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free WGS Stock Alerts